This website uses cookies

We use cookies and website tracking tools to provide you with the best online experience. Learn more in our /en/news/hih-news/privacy-notice/privacy statement.

if you accept, your choice will be valid until cancellation.

If you disallow cookies, functionality of our website might be limited.


HIH News

Study launched in the fight against glioblastoma

Phase I of the clinical trial in the fight against glioblastoma, one of the most aggressive solid tumors, starts today at the University Hospital of Tübingen. This tumor occurs in the central nervous system and is not curable according to current research. The multidisciplinary study team headed by Prof. Dr. Dr. Ghazaleh Tabatabai from the Department of Neurology & Interdisciplinary Neuro-Oncology, together with Prof. Dr. Hans-Georg Rammensee from the Interfaculty Institute of Cell Biology, is using an in-house developed immune stimulator for the first time. The clinical study "Glio-XS15" is supported by funding from the Medical Faculty.

Press release (in German only)

Prof. Dr. Dr. Ghazaleh Tabatabai, Head of the multidisciplinary study team

Foto: Verena Müller